Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an IgG1 monoclonal antibody specifically directed against mouse, rat, and human CD47/IAP. It effectively blocks CD47-mediated signaling to enhance macrophage phagocytic activity, promote immune cell infiltration into tissues, potentially interfere with wound healing processes, and support experimental investigations in oncology and inflammatory disease models, including but not limited to breast cancer research and studies of intestinal mucosal repair mechanisms.

Method: Anti-CD47 antibody treatment and genetic CD47 deletion were studied in normal mice, Cd47-null mice, and intestinal epithelial cell–specific CD47 knockout mice, with biopsy-induced and DSS-induced colonic wound models, complemented by in vitro wound healing assays using primary murine IECs and human colonoid-derived IECs.
Result: Loss or blockade of CD47 impaired intestinal mucosal wound healing in vivo and reduced epithelial cell migration in vitro, associated with decreased β1 integrin signaling and reduced thrombospondin-1 and TGF-β1[1].

Method: Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) was administered intraperitoneally at 400 μg as a single dose 24 h after injury in male C57Bl/6J mice using a biopsy-based mucosal wound model, or intratumorally at 400 μg every 2 days for 30 days in FVB mice bearing MT1A2 tumors.
Result: MIAP410 significantly inhibited mucosal wound healing in C57Bl/6J mice and significantly inhibited tumor growth in MT1A2 tumor–bearing FVB mice.

MIAP410

Mouse/Rat/Human

Monoclonal

Unconjugated